Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Classificação em ações
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Preço da ação
$4.48
Valor de mercado
$4.99B
Variação (1 dia)
-5.20%
Variação (1 ano)
-41.89%
País
CN
Negociar Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Categoria
Healthcare
Receita da Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Receita em Jun 2026 TTM: $703.92M
De acordo com os últimos relatórios financeiros da Shenzhen Salubris Pharmaceuticals Co., Ltd., a receita atual da empresa (TTM) é $703.92M. Em 2024, a empresa obteve uma receita de $549.69M um aumento em relação a a receita do ano 2023, que foi de $475.42M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Shenzhen Salubris Pharmaceuticals Co., Ltd. de 2006 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $703.92M | 14.35% |
| 2025 | $615.57M | 11.98% |
| 2024 | $549.69M | 15.62% |
| 2023 | $475.42M | -5.82% |
| 2022 | $504.79M | 4.91% |
| 2021 | $481.19M | 14.79% |
| 2020 | $419.21M | -34.70% |
| 2019 | $642.00M | -5.07% |
| 2018 | $676.28M | 5.93% |
| 2017 | $638.43M | 15.63% |
| 2016 | $552.15M | 3.10% |
| 2015 | $535.54M | 15.07% |
| 2014 | $465.40M | 21.29% |
| 2013 | $383.71M | 30.83% |
| 2012 | $293.29M | 25.36% |
| 2011 | $233.95M | 18.99% |
| 2010 | $196.62M | 58.00% |
| 2009 | $124.44M | 61.08% |
| 2008 | $77.26M | 61.43% |
| 2007 | $47.86M | 83.90% |
| 2006 | $26.02M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $11.58B | 1,544.78% |
US
|
|
| $34.74B | 4,834.71% |
FR
|
|
| - | - |
JP
|
|
| $20.84B | 2,860.41% |
US
|
|
| - | - |
CH
|
